Innovative Paradigms for ART: Implementation Insights From an Expert Panel

Learn about new paradigms for ART, including two-drug ART regimens and injectable long-acting ART, as a panel of faculty debates the most pressing questions in the field, exploring what the data say, what clinicians think, and what patients want.
Andrea Mantsios, PhD
Anthony M. Mills, MD
Omar Sued, MD, PhD
Babafemi Taiwo, MBBS

ClinicalThought

Current HIV guidelines limit their recommendations for dual ART, but I expect positive data will soon change this.

Omar Sued, MD, PhD Released: September 20, 2019

The question of which patients are candidates for long-acting ART might be a question of which patients want it.

Andrea Mantsios, PhD Released: September 27, 2019

Less frequent dosing may be a welcome theme among HIV drugs under investigation.

Babafemi Taiwo, MBBS Released: October 10, 2019

Why I believe as many as 70% of my patients will be interested in long-acting injectable ART.

Anthony M. Mills, MD Released: December 11, 2019

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?